Last reviewed · How we verify

NCT07253428: Sugamadex

Emergence Agitation

Active, enrolled NA Last updated 28 November 2025
What this trial tests

NA trial testing Neostigmine + Atropine in Emergence Agitation in 486 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 October 2025
Primary endpoint
31 December 2025
31 January 2026

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment486
Start date30 October 2025
Primary completion31 December 2025
Estimated completion31 January 2026
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 60, any sex, with Emergence Agitation or Nasal Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The impact of sugammadex on agitation upon emergence following adult nasal surgeries is an issue which needs to be studied that links anesthetic management with postoperative recovery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neostigmine + Atropine

Trials testing the same drug.

Other recruiting trials for Emergence Agitation

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07253428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing